Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients

<b>Background:</b> The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around 50% of later-stage melanoma patients experiencing recurrence. As variable response...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Joseph C. Broderick, Alexandra M. Adams, Elizabeth L. Barbera, Spencer Van Decar, Guy T. Clifton, George E. Peoples
Format: Article
Langue:anglais
Publié: MDPI AG 2025-06-01
Collection:Vaccines
Sujets:
Accès en ligne:https://www.mdpi.com/2076-393X/13/6/656
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!